Phase I Study of Intra-peritoneal Cantrixil in Patients With Persistent or Recurrent Ovarian Cancer, Fallopian Tube Cancer or Primary Peritoneal Cancer
Phase of Trial: Phase I
Latest Information Update: 31 Jul 2018
At a glance
- Drugs TRXE 002 (Primary)
- Indications Fallopian tube cancer; Ovarian cancer; Peritoneal cancer
- Focus Adverse reactions; First in man; Pharmacokinetics
- Sponsors Kazia Therapeutics
- 22 Jul 2018 Planned End Date changed from 1 Dec 2018 to 1 Dec 2019.
- 22 Jul 2018 Planned primary completion date changed from 1 Oct 2018 to 1 Oct 2019.
- 19 Jun 2018 Results presented in the Kazia Therapeutics media release.
Most Recent Events
Table of Contents
- At a glance
- Trial Overview
- Trial Details
- Trial Centres
- Trial History